Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02725177 · ClinicalTrials.gov registry record · NA
Ocular Sarcoidosis Open Label Trial of ACTHAR Gel
A NA study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT02725177 is a NA study that has completed, run by The Cleveland Clinic. The registered enrollment target is 9 participants.
The verdict
NCT02725177, a NA study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
Treatment with ACTHAR Gel will result in a reduction of ocular inflammation in patients with active ocular sarcoidosis that requires systemic immunosuppressant therapy (hypothesis)
Interventions
- DRUG Repository Corticotropin Injection
- DRUG Repository Corticotropin Injection -Treatment Extension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-07 |
| Est. Completion | 2022-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02725177
The ClinicalTrials.gov registry entry for NCT02725177 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Repository Corticotropin Injection is the first listed.
NCT02725177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02725177 about?
NCT02725177 is a clinical study titled "Ocular Sarcoidosis Open Label Trial of ACTHAR Gel". Treatment with ACTHAR Gel will result in a reduction of ocular inflammation in patients with active ocular sarcoidosis that requires systemic immunosuppressant therapy (hypothesis)
What is the current status of trial NCT02725177?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2016-07. Estimated completion is 2022-03.
What interventions are being tested in trial NCT02725177?
The interventions under investigation include: Repository Corticotropin Injection (DRUG), Repository Corticotropin Injection -Treatment Extension (DRUG).
Who is sponsoring clinical trial NCT02725177?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.